Sustained, high-value insider selling by multiple directors raises concerns about confidence in near-term prospects. Traders should monitor upcoming clinical trial updates or regulatory filings for catalysts that may explain the divestment, and watch for downward pressure on the stock.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $19.67entry
- T+1 · 7mo ago −3.91%α −3.53% · $18.90
- T+5 · 7mo ago −11.49%α −11.54% · $17.41
- T+20 · 6mo ago −10.73%α −14.95% · $17.56
- T+60 · 4mo ago +19.22%α +14.88% · $23.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at Dyne Therapeutics (DYN) sold over $11.4 million in shares over the past 7 days, including a $4.3 million sale by Dirk Kersten on April 17. The cluster represents more than 0.35% of the company's $3.2B market cap, signaling notable insider selling.
Key Financial Metrics
Key Facts
- Director Dirk Kersten sold 211,974 shares on April 17 for $4.3 million, the largest single transaction in the cluster.
- Director Jason Rhodes sold 143,175 shares across two days (April 21 and 22) for $2.83 million.
- Total insider selling over 7 days amounts to $11.4 million across 7 transactions by two directors.
- All transactions were open-market sales (code S), indicating deliberate divestment.
- Recent insider activity over the past 30 days totals $13.4 million in sales, suggesting sustained selling pressure.
Financial Impact
$11.4 million in insider sales over 7 days (0.35% of $3.2B market cap)
Risk Factors
- Loss of insider confidence may signal upcoming negative developments or lack of upside catalysts.
- Heavy selling could precede downward earnings or pipeline updates.
- Potential for increased share volatility if retail investors react to insider moves.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1776975352606 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers